The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Treatment of Primary Sjögren Syndrome: A Systematic Review
Abstract
CONTEXT: A variety of topical and systemic drugs are available to treat primary Sjögren syndrome, although no evidence-based therapeutic guidelines are currently available. OBJECTIVE: To summarize evidence on primary Sjögren syndrome drug therapy from randomized controlled trials. DATA SOURCES: We searched MEDLINE and EMBASE for articles on drug therapy for primary Sjögren syndrome published between January 1, 1986, and April 30, 2010. STUDY SELECTION: Controlled trials of topical and systemic drugs including adult patients with primary Sjögren syndrome were selected as the primary information source. RESULTS: The search strategy yielded 37 trials. A placebo-controlled trial found significant improvement in the Schirmer and corneal staining scores, blurred vision, and artificial tear use in patients treated with topical ocular 0.05% cyclosporine. Three placebo-controlled trials found that pilocarpine was associated with improvements in dry mouth (61%-70% vs 24%-31% in the placebo group) and dry eye (42%-53% vs 26%). Two placebo-controlled trials found that cevimeline was associated with improvement in dry mouth (66%-76% vs 35%-37% in the placebo group) and dry eye (39%-72% vs 24%-30%). Small trials (<20 patients) found no significant improvement in sicca outcomes for oral prednisone or hydroxychloroquine and limited benefits for immunosuppressive agents (azathioprine and cyclosporine). A large trial found limited benefits for oral interferon alfa-2a. Two placebo-controlled trials of infliximab and etanercept did not achieve the primary outcome (a composite visual analog scale measuring joint pain, fatigue, and dryness); neither did 2 small trials (<30 patients) testing rituximab, although significant results were observed in some secondary outcomes and improvement compared with baseline. CONCLUSIONS: In primary Sjögren syndrome, evidence from controlled trials suggests benefits for pilocarpine and cevimeline for sicca features and topical cyclosporine for moderate or severe dry eye. Anti-tumor necrosis factor agents have not shown clinical efficacy, and larger controlled trials are needed to establish the efficacy of rituximab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., Gabriel, S., Hirsch, R., Hochberg, M. C., Hunder, G. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23176 · Cited by 5,499
Seror, R., Ravaud, P., Bowman, S. J., Baron, G., Tzioufas, A., Theander, E., Gottenberg, J.-E., Bootsma, H., Mariette, X., & Vitali, C. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.110619 · Cited by 965
Self-citationSall, K., Stevenson, O. D., Mundorf, T. K., & Reis, B. L. (2000) · Ophthalmology · doi:10.1016/s0161-6420(99)00176-1 · Cited by 916
Clinical Manifestations and Early Diagnosis of Sjögren Syndrome
Kassan, S. S., & Moutsopoulos, H. M. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.12.1275 · Cited by 698
Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study
Pijpe, J., van Imhoff, G. W., Spijkervet, F. K. L., Roodenburg, J. L. N., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G. M., & Bootsma, H. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21260 · Cited by 500
Meijer, J. M., Meiners, P. M., Vissink, A., Spijkervet, F. K. L., Abdulahad, W., Kamminga, N., Brouwer, E., Kallenberg, C. G. M., & Bootsma, H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27314 · Cited by 488
Vivino, F. B. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.2.174 · Cited by 448
Mariette, X., Ravaud, P., Steinfeld, S., Baron, G., Goetz, J., Hachulla, E., Combe, B., Puéchal, X., Pennec, Y., Sauvezie, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20146 · Cited by 437
Dass, S., Bowman, S. J., Vital, E. M., Ikeda, K., Pease, C. T., Hamburger, J., Richards, A., Rauz, S., & Emery, P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083865 · Cited by 431
Stevenson, D., Tauber, J., & Reis, B. L. (2000) · Ophthalmology · doi:10.1016/s0161-6420(00)00035-x · Cited by 425
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Gottenberg, J.-E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., Larroche, C., Soubrier, M., Bouillet, L., Dougados, M., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029694 · Cited by 401
Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome
Marsh, P., & Pflugfelder, S. C. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90171-9 · Cited by 355
Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)
Devauchelle‐Pensec, V., Pennec, Y., Morvan, J., Pers, J., Daridon, C., Jousse‐Joulin, S., Roudaut, A., Jamin, C., Renaudineau, Y., Roué, I. Q., et al. (2007) · Arthritis Care & Research · doi:10.1002/art.22536 · Cited by 315
Sankar, V., Brennan, M. T., Kok, M. R., Leakan, R. A., Smith, J. A., Manny, J., Baum, B. J., & Pillemer, S. R. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20299 · Cited by 307
Seror, R., Sordet, C., Guillevin, L., Hachulla, E., Masson, C., Ittah, M., Candon, S., Le Guern, V., Aouba, A., Sibilia, J., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057919 · Cited by 305
Primary Sjögren's syndrome: new clinical and therapeutic concepts
Ramos-Casals, M., Tzioufas, A. G., & Font, J. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.025676 · Cited by 295
Self-citationPetrone, D., Condemi, J. J., Fife, R., Gluck, O., Cohen, S., & Dalgin, P. (2002) · Arthritis & Rheumatism · doi:10.1002/art.510 · Cited by 282
Steinfeld, S. D., Tant, L., Burmester, G. R., Teoh, N. K., Wegener, W. A., Goldenberg, D. M., & Pradier, O. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2018 · Cited by 258
Pflugfelder, S. C., Maskin, S. L., Anderson, B., Chodosh, J., Holland, E. J., De Paiva, C. S., Bartels, S. P., Micuda, T., Proskin, H. M., & Vogel, R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.04.052 · Cited by 233
Kruize, A. A., Hené, R. J., Kallenberg, C. G., van Bijsterveld, O. P., van der Heide, A., Kater, L., & Bijlsma, J. W. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.5.360 · Cited by 226
Pers, J., Devauchelle, V., Daridon, C., Bendaoud, B., Berre, R. L., Bordron, A., Hutin, P., Renaudineau, Y., Dueymes, M., Loisel, S., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22603 · Cited by 221
Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study
Fox, R., Dixon, R., Guarrasi, V, & Krubel, S. (1996) · Lupus · doi:10.1177/0961203396005001081 · Cited by 217
Cevimeline for the Treatment of Xerostomia in Patients With Sjögren Syndrome: A Randomized Trial
Fife, R. S., Chase, W. F., Dore, R. K., Wiesenhutter, C. W., Lockhart, P. B., Tindall, E., & Suen, J. Y. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.11.1293 · Cited by 193
Progression of salivary gland dysfunction in patients with Sjögren's syndrome
Pijpe, J., Kalk, W. W. I., Bootsma, H., Spijkervet, F. K. L., Kallenberg, C. G. M., & Vissink, A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.052647 · Cited by 180
Tauber, J., Davitt, W. F., Bokosky, J. E., Nichols, K. K., Yerxa, B. R., Schaberg, A. E., LaVange, L. M., Mills-Wilson, M. C., & Kellerman, D. J. (2004) · Cornea · doi:10.1097/01.ico.0000133993.14768.a9 · Cited by 168
A Comparison of Vitamin A and Cyclosporine A 0.05% Eye Drops for Treatment of Dry Eye Syndrome
Kim, E. C., Choi, J.-S., & Joo, C.-K. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.08.015 · Cited by 166
Cummins, M. J., Papas, A., Kammer, G. M., & Fox, P. C. (2003) · Arthritis Care & Research · doi:10.1002/art.11199 · Cited by 156
A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases
Ramos‐Casals, M., Brito‐Zerón, P., Muñoz, S., & Soto, M.-J. (2008) · Medicine · doi:10.1097/md.0b013e318190f170 · Cited by 152
Self-citationPijpe, J., Meijer, J., Bootsma, H., van der Wal, J. E., Spijkervet, F. K. L., Kallenberg, C. G. M., Vissink, A., & Ihrler, S. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24903 · Cited by 150
Tsifetaki, N., Kitsos, G., Paschides, C. A., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2002.003889 · Cited by 142
Ono, M., Takamura, E., Shinozaki, K., Tsumura, T., Hamano, T., Yagi, Y., & Tsubota, K. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.02.010 · Cited by 134
Papas, A., Sherrer, Y., Charney, M. W., Golden, H. E., Medsger, T. A., Walsh, B. T., Trivedi, M., Goldlust, B., & Gallagher, S. C. (2004) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000135553.08057.21 · Cited by 126
Tishler, M., Yaron, I., Shirazi, I., & Yaron, M. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.4.253 · Cited by 126
Forsblad‐d’Elia, H., Carlsten, H., Labrie, F., Konttinen, Y. T., & Ohlsson, C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0106 · Cited by 112
Hartkamp, A., Geenen, R., Godaert, G. L. R., Bootsma, H., Kruize, A. A., Bijlsma, J. W. J., & Derksen, R. H. W. M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071563 · Cited by 108
Prednisone and piroxicam for treatment of primary Sjögren's syndrome.
Fox, P. C., Datiles, M. B., Atkinson, J. C., Macynski, A. A., Scott, J. T., Fletcher, D., Valdez, I. H., Kurrasch, R., Delapenha, R., & Jackson, W. (1993) · PubMed · Cited by 96
Leung, K., McMillan, A. S., Wong, M. C. M., Leung, W. K., Mok, M. Y., & Lau, C. S. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0723-x · Cited by 63
Miyawaki, S., Nishiyama, S., & Matoba, K. (1999) · Internal Medicine · doi:10.2169/internalmedicine.38.938 · Cited by 62
Hong, S., Kim, T., Chung, S., Kim, E. K., & Seo, K. Y. (2007) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.0091 · Cited by 61
Wu, C.-H., Hsieh, S., Lee, K., et al. (2006) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60266-7 · Cited by 54
Zidovudine in primary Sjögren's syndrome
Steinfeld, S. D., Demols, P., Vooren, J. P. V., Cogan, E., & Appelboom, T. (1999) · Rheumatology · doi:10.1093/rheumatology/38.9.814 · Cited by 45
Virkki, L. M., Porola, P., Forsblad‐d’Elia, H., Valtýsdóttir, S. T., Solovieva, S. A., & Konttinen, Y. T. (2009) · Arthritis Care & Research · doi:10.1002/acr.20022 · Cited by 44
Efficacy prediction of cevimeline in patients with Sjögren’s syndrome
Yamada, H., Nakagawa, Y., Wakamatsu, E., Sumida, T., Yamachika, S., Nomura, Y., Mishima, K., & Saito, I. (2007) · Clinical Rheumatology · doi:10.1007/s10067-006-0507-8 · Cited by 42
A Double-blind, Cross-over, Study of Oral N-Acetylcysteine in Sjögren’s Syndrome
Walters, M. T., Rubin, C. E., Keightley, S. J., et al. (1986) · Scandinavian Journal of Rheumatology · doi:10.1080/15027732.1986.12461423 · Cited by 38
Kasama, T., Shiozawa, F., Isozaki, T., Matsunawa, M., Wakabayashi, K., Odai, T., Yajima, N., Miwa, Y., Negishi, M., & Ide, H. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0078-4 · Cited by 23
Lamivudine is not effective in primary Sjögren's syndrome
Gescuk, B. D., Wu, A. J., Whitcher, J. P., Daniels, T. E., Lund, S., Fye, K., & Davis, J. C. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031393 · Cited by 14
Ho (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200110)44:10 · Cited by 3
Cited by
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
TFOS DEWS II Management and Therapy Report
Jones, L., Downie, L. E., Korb, D., Benitez-del-Castillo, J. M., Dana, R., Deng, S. X., Dong, P. N., Geerling, G., Hida, R. Y., Liu, Y., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.05.006 · Cited by 1,422
Mariette, X., & Criswell, L. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1702514 · Cited by 947
Brito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Sivils, K., Theander, E., Tzioufas, A., & Ramos-Casals, M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.47 · Cited by 868
Self-citationEULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies
Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., Bootsma, H., De Vita, S., Dörner, T., Fisher, B. A., Gottenberg, J.-E., Hernandez-Molina, G., Kocher, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216114 · Cited by 732
Self-citation
Metadata
- Authors
- Ramos-Casals, M., Tzioufas, A. G., Stone, J. H., Sisó, A., & Bosch, X.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2010-07-28
- Volume
- 304
- Issue
- 4
- Pages
- 452
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2078958726
- Cited by
- 381
- References
- 47
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.